Texas Permanent School Fund Has $790,000 Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)

Texas Permanent School Fund decreased its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Get Rating) by 6.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 54,478 shares of the company’s stock after selling 3,515 shares during the period. Texas Permanent School Fund owned approximately 0.07% of Myriad Genetics worth $790,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Duality Advisers LP acquired a new position in shares of Myriad Genetics in the 4th quarter valued at $767,000. Fisher Asset Management LLC grew its holdings in shares of Myriad Genetics by 51.0% in the 4th quarter. Fisher Asset Management LLC now owns 190,383 shares of the company’s stock valued at $2,762,000 after buying an additional 64,276 shares during the period. ProShare Advisors LLC grew its holdings in shares of Myriad Genetics by 8.8% in the 4th quarter. ProShare Advisors LLC now owns 19,298 shares of the company’s stock valued at $280,000 after buying an additional 1,554 shares during the period. State of New Jersey Common Pension Fund D grew its holdings in shares of Myriad Genetics by 19.6% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 119,759 shares of the company’s stock valued at $1,738,000 after buying an additional 19,665 shares during the period. Finally, NorthCrest Asset Manangement LLC grew its holdings in shares of Myriad Genetics by 14.9% in the 4th quarter. NorthCrest Asset Manangement LLC now owns 11,950 shares of the company’s stock valued at $173,000 after buying an additional 1,550 shares during the period. Institutional investors and hedge funds own 99.08% of the company’s stock.

Insider Transactions at Myriad Genetics

In other news, COO Nicole Lambert sold 6,433 shares of the business’s stock in a transaction dated Monday, March 27th. The shares were sold at an average price of $23.48, for a total transaction of $151,046.84. Following the transaction, the chief operating officer now directly owns 240,506 shares in the company, valued at approximately $5,647,080.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.00% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on MYGN. StockNews.com began coverage on shares of Myriad Genetics in a research report on Thursday, March 16th. They issued a “hold” rating on the stock. Stephens boosted their price objective on shares of Myriad Genetics from $17.00 to $24.00 and gave the company an “equal weight” rating in a research report on Monday, March 6th. Finally, Raymond James boosted their price objective on shares of Myriad Genetics from $25.00 to $27.00 and gave the company an “outperform” rating in a research report on Friday, March 3rd. Three equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.00.

Myriad Genetics Price Performance

Shares of NASDAQ:MYGN opened at $18.59 on Wednesday. The company’s 50-day moving average price is $21.86 and its two-hundred day moving average price is $19.79. Myriad Genetics, Inc. has a one year low of $13.92 and a one year high of $28.18. The stock has a market capitalization of $1.52 billion, a PE ratio of -10.33 and a beta of 1.83.

Myriad Genetics (NASDAQ:MYGN – Get Rating) last released its quarterly earnings data on Wednesday, May 3rd. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $181.20 million for the quarter, compared to analyst estimates of $171.56 million. Myriad Genetics had a negative return on equity of 7.42% and a negative net margin of 21.05%. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.14) earnings per share. On average, analysts anticipate that Myriad Genetics, Inc. will post -0.68 earnings per share for the current fiscal year.

About Myriad Genetics

(Get Rating)

Myriad Genetics, Inc engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk of developing a disease later in life.